Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Selpercatinib Effective in RET Fusion–Positive NSCLC, Irrespective of Prior Therapies

June 5th 2021

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Aumolertinib Prolongs Survival, Duration of Response in NSCLC

June 5th 2021

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Amivantamab/Lazertinib Yields Durable Responses in Osimertinib-Relapsed, Chemo-Naïve EGFR+ NSCLC

June 5th 2021

Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.

Patritumab Deruxtecan Displays Durable Efficacy in EGFR TKI–Resistant EGFR+ NSCLC

June 4th 2021

Patritumab deruxtecan was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR TKIs.

Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC

June 4th 2021

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.

Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC

June 4th 2021

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

Nivolumab/Ipilimumab Plus Chemotherapy Shows Durable Benefit in Advanced NSCLC

June 4th 2021

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.

CLN-081 Elicits Encouraging Efficacy and Safety in EGFR Exon 20–Positive NSCLC

June 4th 2021

CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Updated Findings Confirm Long-Term Survival Benefit with Durvalumab in NSCLC

June 4th 2021

Data from an updated analysis of the phase 3 PACIFIC trial indicate that treatment with durvalumab after chemoradiotherapy is associated with long-term survival improvements in patients with unresectable stage III non-small cell lung cancer.

4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC

June 4th 2021

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib Elicits Anticancer Activity in Platinum-Pretreated EGFR Exon 20 Insertion+ Advanced NSCLC

June 4th 2021

Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Concurrent Pembrolizumab Plus Chemoradiation Therapy Elicits Antitumor Activity in NSCLC

June 4th 2021

Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.

Brigatinib Maintains Long-Term Efficacy in Crizotinib-Refractory ALK+ NSCLC

June 4th 2021

Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC

June 4th 2021

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Surgical Resectability in Stage IIIA-N2 NSCLC

June 3rd 2021

Christian Grohé, MD, and Gary Doherty, MRCP, PhD, consider factors that may influence the resectability of patients with stage IIIA-N2 disease, such as biomarker status, performance status, and imaging results.

Potential Challenges of Molecular Testing in NSCLC

June 3rd 2021

A panel of experts in the management of lung cancer share key insights into challenges associated with retesting for driver mutations, tumor heterogeneity, and potential differences between biopsy and surgical sample test results.

Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLC

June 2nd 2021

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

Nivolumab/Ipilimumab Approved in Europe for Frontline Unresectable Malignant Pleural Mesothelioma

June 2nd 2021

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

June 1st 2021

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC

May 28th 2021

The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.